CRISPR Therapeutics AG (CRSP) Enterprise Value (2015 - 2026)

CRISPR Therapeutics AG has disclosed Enterprise Value across 12 years of filings, most recently posting -$2.4 billion for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$2.4 billion, down 31.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 billion (down 31.61% YoY), and the FY2025 annual result was -$2.0 billion, down 23.06% from the prior year.
• Enterprise Value came in at -$2.4 billion for Q1 2026 at CRISPR Therapeutics AG, down from -$2.0 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$1.6 billion in Q4 2024 to a low of -$2.4 billion in Q1 2026.
• The 5-year median for Enterprise Value is -$1.9 billion (2022), against an average of -$1.9 billion.
• Across the five-year window, Enterprise Value increased 23.7% in 2022 and plunged 31.61% in 2026, its largest moves.
• CRISPR Therapeutics AG's Enterprise Value stood at -$1.8 billion in 2022, then rose by 6.7% to -$1.7 billion in 2023, then increased by 5.2% to -$1.6 billion in 2024, then fell by 23.06% to -$2.0 billion in 2025, then dropped by 23.58% to -$2.4 billion in 2026.
• The last three Enterprise Value figures came in at -$2.4 billion (Q1 2026), -$2.0 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.